TCGA and ACRG driven molecular classification identifies biologically distinct gastric cancer subtypes in Iranian patients

Gastric cancer (GC) is a highly heterogeneous disease with diverse molecular and clinical features. Molecular classifications by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) have improved our understanding of GC biology and therapeutic stratification. Yet their clinical utility is limited by high cost and technically complex methods, and no comprehensive studies have been conducted in the Iranian population. In this study, we applied a panel-based approach integrating PCR-based microsatellite instability (MSI) analysis, quantitative real-time PCR for gene expression profiling, and Sanger sequencing for hotspots mutation detection to assess key molecular features, including EBV infection, MSI status, TP53 mutations, and expression of CDH1, VIM, MDM2, and CDKN1A. Statistical analyses were performed using appropriate parametric and nonparametric tests, with p < 0.05 considered statistically significant. Using the TCGA framework, tumors were classified as EBV-positive (7.3%), MSI-H (9.8%) and MSI-L (7.3%), genomically stable (GS, 36.5%), chromosomal instability (CIN, 29.2%), with 9.8% remaining unclassified. Application of the ACRG classification identified MSI-H (9.8%) and MSI-L (7.3%), 19.5% cases as MSS/EMT (CDH1-low, VIM-high), 36.5% as MSS/TP53− (P21-low and/or MDM2-high), and 26.8% as MSS/TP53+. Notably, MDM2 expression showed a significant association with tumor size ( P = 0.0163), and tumor size varied significantly among subtypes defined by the ACRG classification ( P = 0.0152). These findings demonstrate that both TCGA and ACRG classifications, particularly the latter, can be effectively applied to a moderately sized cohort, revealing biologically and clinically distinct GC subtypes. These findings demonstrate the feasibility of applying surrogate TCGA and ACRG molecular classification frameworks in an Iranian gastric cancer cohort and provide a basis for further validation in larger studies.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-18
DOI
https://doi.org/10.1007/s12672-026-06278-1
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TCGA and ACRG driven molecular classification identifies biologically distinct gastric cancer subtypes in Iranian patients

Seyed Mohammad Akrami, Reza Shirkoohi, Amirhossein Razavirad, Àmirnader Emami Razavi et al.
1 links
Discover Oncology
Gastric Cancer Management and Outcomes
article

TCGA and ACRG driven molecular classification identifies biologically distinct gastric cancer subtypes in Iranian patients

Seyed Mohammad Akrami, Reza Shirkoohi, Amirhossein Razavirad, Àmirnader Emami Razavi, Zeinab Jamali
article en

Abstract

Gastric cancer (GC) is a highly heterogeneous disease with diverse molecular and clinical features. Molecular classifications by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) have improved our understanding of GC biology and therapeutic stratification. Yet their clinical utility is limited by high cost and technically complex methods, and no comprehensive studies have been conducted in the Iranian population. In this study, we applied a panel-based approach integrating PCR-based microsatellite instability (MSI) analysis, quantitative real-time PCR for gene expression profiling, and Sanger sequencing for hotspots mutation detection to assess key molecular features, including EBV infection, MSI status, TP53 mutations, and expression of CDH1, VIM, MDM2, and CDKN1A. Statistical analyses were performed using appropriate parametric and nonparametric tests, with p < 0.05 considered statistically significant. Using the TCGA framework, tumors were classified as EBV-positive (7.3%), MSI-H (9.8%) and MSI-L (7.3%), genomically stable (GS, 36.5%), chromosomal instability (CIN, 29.2%), with 9.8% remaining unclassified. Application of the ACRG classification identified MSI-H (9.8%) and MSI-L (7.3%), 19.5% cases as MSS/EMT (CDH1-low, VIM-high), 36.5% as MSS/TP53− (P21-low and/or MDM2-high), and 26.8% as MSS/TP53+. Notably, MDM2 expression showed a significant association with tumor size ( P = 0.0163), and tumor size varied significantly among subtypes defined by the ACRG classification ( P = 0.0152). These findings demonstrate that both TCGA and ACRG classifications, particularly the latter, can be effectively applied to a moderately sized cohort, revealing biologically and clinically distinct GC subtypes. These findings demonstrate the feasibility of applying surrogate TCGA and ACRG molecular classification frameworks in an Iranian gastric cancer cohort and provide a basis for further validation in larger studies.

Discover Oncology
Imam Khomeini Hospital (IR), Tehran University of Medical Sciences (IR)
Tehran University of Medical Sciences and Health Services
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon